Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018-Reference-Cited by-同舟云学术

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

Author:

MacDonald Karen M.¹^ORCID,Kavati Abhishek²^ORCID,Ortiz Benjamin³^ORCID,Alhossan Abdulaziz⁴^ORCID,Lee Christopher S.¹⁵^ORCID,Abraham Ivo¹⁶⁷⁸^ORCID

Affiliation:

1. Division of Research, Matrix45, Tucson, AZ, USA

2. Health Economics & Outcomes Research, Novartis, East Hanover, NJ, USA

3. Clinical Development & Medical Affairs, Novartis, East Hanover, NJ, USA

4. College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

5. Boston College, Connell School of Nursing, Boston, MA, USA

6. Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA

7. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

8. Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA

Funder

manuscript from Matrix45

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

Reference88 articles.

1. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network; 2018.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of atopic conditions in children with chronic urticaria;The Journal of Allergy and Clinical Immunology: In Practice;2024-09